Jenny E. Freeman, M.D. (co-founder & ceo)
Jenny brings over 25 years of broad hands-on experience in medicine, research and entrepreneurship including cardiothoracic surgery, biomedical research of subcellular processes and medical device innovation. Previously she was founding CEO of HyperMed, Inc., a medical imaging company based on a technology to measure tissue oxygenation. Jenny holds an M.D. from New York University and a B.A. from Yale University.
Alexander Panasyuk, Ph.D (co-founder & cto)
Alexander is an established expert in hardware and software integration and data analysis. He is an author on each of Respiratory Motion's patents. Previously, Alexander was the primary development engineer at Hypermed, Inc. His experience includes the Infrared-Optical Telescope Array project at the Harvard-Smithsonian Center for managing a space-born instrument mounted on a Solar & Heliospheric Observatory satellite. Alexander holds a Ph.D. in Applied Physics from the Russian Academy of Sciences and a B.S. and M.S. from the Moscow Institute for Physics and Technology.
Kamen Bliznashki, M.B.A. (vp of finance & business development)
Kamen brings investment banking experience from the medical devices, healthcare services, and pharmaceutical industries. Previously he worked at Deutsche Bank Mergers & Acquisitions in New York and London. Kamen holds an M.B.A. from Harvard Business School and a B.S. from Georgetown University.
Malcolm Bock (vp of engineering)
Malcolm has over 25 years experience in the medical device industry. Previously he worked at Covidien in their Vascular Therapies Business as Sr. Director of R&D responsible for global development of the DVT Prevention Franchise. Malcolm has a successful track record of bringing unique proprietary technology to market successfully. He received the Covidien Inventor of the year award in 2011. Malcolm holds a B.S. from Cornell University.
Jack Auer (vp of marketing)
Jack has over 20 years of experience in the medical device industry. He was most recently Vice President of Marketing and Sales with Xhale Assurance, a start up pulse oximetry sensor company and previously Vice President of Marketing with Oridion Capnography, Inc. (now a Covidien company), a global medical device company that specializes in the development and marketing of capnography capital and consumable products. Prior to Oridion, Jack held senior marketing positions at Siemens Medical Systems USA, Inc. / Draeger Medical Systems, Inc. Jack holds a B.A. from the Wharton School at the University of Pennsylvania.
Board of Directors
Svetlana Panasyuk, Ph.D.,
Dr. Svetlana Panasyuk brings strong software, image processing and algorithm skills critical for R&D, commercialization, and corporate partnerships. Previously she was instrumental in developing the first clinical hyperspectral systems. Dr. Panasyuk’s training includes a Master’s Degree from Moscow Institute of Technology, a PhD in Physics from Massachusetts Institute of Technology, two Harvard fellowships and an MBA from Babson College. She has subsequently accrued extensive industry experience in all aspects of algorithm and software development, scientific experiment and data processing and the application of these skills toward the development of optical instrumentation and medical devices.
Don Freeman, Ph.D., (no relationship to Dr. Jenny Freeman)
Dr. Freeman brings extensive experience in the business of healthcare and investment banking. Don is an inventor on 20 US patents, has run over 10 life science companies, and served on the Board of Directors of over 20 healthcare companies, public and private. Most recently he was a Board Member of Pluramed, leading to the company’s exit to Sanofi. Before retiring in 2002, Dr. Freeman was President & CEO of HydroCision, a privately owned medical products company. From 1996 until 2000, Dr. Freeman was Chairman, CEO and a Director of RadioMed Corporation, before its acquisition by a major foreign corporation in 2000. Prior to 1996, Dr. Freeman was a Principal of Grayson & Associates, Inc., an investment banking firm specializing in healthcare. Previously, he had roles as President and CEO of Intra-Sonix, Inc., President and CEO of Xenotech and President of Davol, Inc. Following the acquisition of Davol by C. R. Bard, Inc., he served as a Group Vice President of C. R. Bard. Don received his PhD in Chemistry from the University of Maryland and was a Post Doctoral Fellow at Duke University.
Peter Aranow, M.B.A.
Mr. Aranow is a private investor and member of the Board of Directors of the National Patient Safety Foundation. During his career, Mr. Aranow has spent 17 years in investment banking with Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.
Robert J. Manning, M.A.
Mr. Manning is President of Gray's Point Investments. He is currently a director at Avaxia Biologics and was previously a director at SmartCells and Boston Heart Diagnostics. Mr. Manning retired after more than 25 years with Citibank and Citigroup, where he served as Managing Director and Head of Corporate Finance for Citigroup in Japan where units under his supervision raised more than $50 Billion in private market financings for clients. He served as Chief of Staff for the U.S. Corporate Finance business of Citibank, was previously Global Structured Trade Finance Head and earlier in his career held a variety of product management and country management positions in the U.S., the Middle East, and Africa. Mr. Manning has an M.A. from the Fletcher School of Law and Diplomacy and a B.A. from Brown University in International Relations.
John Friedman, J.D.
Mr. Friedman is the Founding and Managing Partner of Easton Capital Group. Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, he was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. Previously, Mr. Friedman was an attorney with Sullivan and Cromwell. He currently serves on the Boards of Promedior, Trellis Bioscience, Cardiovascular Systems, PreceptiMed, TigerText, Within3, and Precise Light. He was also co-chairman of the President's Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art and The Sculpture Center.